Immune and autoimmune medications

Showing 43 of 43 medications in immune and autoimmune medications. Jump to clinical reference & sources below

Filter by condition:
Showing 43 of 43 medications

Drug Classes & How They Work

  • Clinical guidelines from the American College of Rheumatology (ACR) classify systemic autoimmune therapies into conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), targeted synthetic DMARDs (tsDMARDs), biologic DMARDs (bDMARDs), and transplant calcineurin/mTOR inhibitors (1.1) (2.1) (4.1).
Immunomodulator Class Representative Active Ingredients Primary Molecular Target Primary Autoimmune & Transplant Indications
Conventional synthetic DMARDs (csDMARDs) Methotrexate, hydroxychloroquine (Plaquenil), sulfasalazine, leflunomide (Arava), azathioprine (Imuran) Dihydrofolate reductase/AICAR transformylase, lysosomal TLR modulation, or dihydroorotate dehydrogenase inhibition Foundational therapy in rheumatoid arthritis, systemic lupus erythematosus (hydroxychloroquine), and psoriatic arthritis (1.1) (2.1)
Targeted synthetic PDE4 inhibitors Apremilast (Otezla) Inhibits intracellular phosphodiesterase-4, increasing cAMP to downregulate TNF-alpha, IL-17, and IL-23 Plaque psoriasis, psoriatic arthritis, and oral ulcers of Behcet's disease; does not require routine lab tuberculosis/organ monitoring (2.1) (3.1)
Janus kinase (JAK) inhibitors (tsDMARDs) Upadacitinib (Rinvoq), tofacitinib (Xeljanz), baricitinib (Olumiant) Inhibits intracellular JAK1/JAK2/JAK3 tyrosine kinases that transduce cytokine receptor signals Moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and ulcerative colitis (1.1) (2.1)
Transplant & autoimmune calcineurin / antimetabolite agents Tacrolimus (Prograf, Advagraf), cyclosporine (Neoral), mycophenolate mofetil (CellCept), mycophenolic acid (Myfortic) Inhibits calcineurin IL-2 transcription or inosine monophosphate dehydrogenase (IMPDH) lymphocyte proliferation Solid-organ transplant rejection prophylaxis, lupus nephritis, and severe refractory autoimmune disease; narrow therapeutic index (2.1) (4.1)
Systemic corticosteroids Prednisone, methylprednisolone (Medrol), budesonide, dexamethasone Broad genomic suppression of pro-inflammatory transcription factors (NF-kappaB, AP-1) Acute autoimmune flare bridging therapy; tapered to lowest effective dose to minimize long-term steroid toxicity (1.1) (2.1)

Immune and autoimmune medications: Clinical Overview & Scope

Dosage Forms, Release Profiles & Devices

  • Dosing schedules and formulation bioavailability across immunomodulators carry high-alert safety requirements (2.1) (4.1).
  • Oral methotrexate for autoimmune conditions (rheumatoid arthritis or psoriasis) is dosed strictly once weekly on the same designated day of the week, never once daily, as accidental daily dosing causes fatal pancytopenia, hepatotoxicity, and gastrointestinal mucositis (1.1) (2.1).
  • Apremilast (Otezla) utilizes a 5-day starter pack titration (escalating from 10 mg on Day 1 to 30 mg twice daily by Day 6) to minimize early gastrointestinal diarrhea and nausea (2.1).
  • In transplant medicine, immediate-release tacrolimus twice daily (Prograf) and extended-release tacrolimus once daily (Advagraf / Astagraf XL), as well as non-modified versus microemulsion cyclosporine (Neoral), have distinct pharmacokinetic curves and cannot be substituted without transplant team therapeutic drug monitoring (TDM) of whole-blood trough levels (2.1) (4.1).

Key Safety, Storage & Monitoring Points

  • Systemic immunosuppressants and targeted DMARDs require comprehensive baseline and periodic clinical monitoring (1.1) (2.1).
  • Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, upadacitinib) carry boxed warnings for serious bacterial, mycobacterial, invasive fungal, and viral infections (including tuberculosis and herpes zoster reactivation), mortality, malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism; latent tuberculosis screening (IGRA or PPD) and baseline complete blood counts, liver enzymes, and lipid panels are required prior to initiation (1.1) (2.1).
  • Live attenuated vaccines (such as MMR, varicella, or intranasal live influenza) must be avoided during potent immunosuppressive therapy (1.1) (2.1).
  • Patients taking hydroxychloroquine (Plaquenil) require baseline and periodic ophthalmologic retinal screening (OCT and visual fields) to monitor for cumulative dose-related retinopathy, kept below ≤5.0 mg/kg/day of actual body weight (1.1) (2.1).
  • Leflunomide, methotrexate, and mycophenolate carry boxed warnings for severe embryofetal toxicity and teratogenicity (2.1) (4.1).

Ordering & Prescription Checklist for U.S. Patients

  • Match your prescription details: Confirm the active ingredient name, exact milligram or microgram strength, release profile, and package quantity on your U.S. prescription (2.1) (4.1).
  • Licensed pharmacist review: Every order undergoes a dosing, strength, and drug-interaction check in under 1 business day, followed by a mandatory pharmacist consultation before dispatch (3.1).
  • Transparent USD pricing and shipping: Room-temperature medications ship for $14.99 USD flat rate and cold-chain medications ship in $29.99 USD insulated coolers via tracked Canada Post and USPS delivery.
  • Need help matching a product or transferring an Rx? Call 1-888-868-1920 (Monday - Friday: 9:00AM - 6:00PM; Saturday - Sunday: Closed) or review our step-by-step ordering guide and prescription requirements.

Frequently Asked Questions

Why is methotrexate taken only once a week for rheumatoid arthritis and psoriasis?

At low once-weekly doses (typically 7.5 mg to 25 mg once per week), methotrexate acts as an anti-inflammatory immunomodulator rather than a cytotoxic chemotherapy agent (1.1) (2.1). Taking methotrexate daily by mistake is a dangerous medical emergency that causes severe bone marrow suppression and liver injury.

How does Otezla (apremilast) differ from biologic injections or JAK inhibitors?

Otezla is an oral phosphodiesterase-4 (PDE4) inhibitor that modulates intracellular cyclic AMP rather than completely blocking a single cytokine receptor or JAK pathway (2.1) (3.1). Because it does not cause broad systemic immunosuppression, its prescribing label does not require routine tuberculosis screening or periodic laboratory blood count monitoring.

Why are periodic eye exams recommended for patients taking Plaquenil (hydroxychloroquine) long-term?

Over many years of continuous use, hydroxychloroquine can gradually bind to melanin in the retinal pigment epithelium (1.1) (2.1). Keeping the daily dose at or below 5 mg/kg of actual body weight and performing regular optical coherence tomography (OCT) eye screenings detects early subclinical changes long before vision is affected.

References & Official Clinical Sources

Pharmacological classifications, mechanism comparisons, dosing-form distinctions, and clinical safety notes for immune and autoimmune medications are compiled from official regulatory prescribing monographs and medical practice guidelines:

Need help finding your medication? Call 1-888-868-1920.

Call 1-888-868-1920Help